OncoMatch/Clinical Trials/NCT05558007
Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Is NCT05558007 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Tadalafil 5mg and BZ371A for erectile dysfunction following radical prostatectomy.
Treatment: Tadalafil 5mg · BZ371A — To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Demographics
Prior therapy
Must have received: radical prostatectomy
RP due to prostate cancer without metastasis; RP performed less than 60 days before the screening visit
Must have received: phosphodiesterase type 5 inhibitor (tadalafil)
Continuous use of 5mg Tadalafil from the 30th up to the 60th day after RP
Cannot have received: radiation therapy
Necessity of other therapy for prostate cancer than RP, including radiation therapy or hormone therapy
Cannot have received: hormone therapy
Necessity of other therapy for prostate cancer than RP, including radiation therapy or hormone therapy
Cannot have received: male hormone
Current male hormone use
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05558007 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, hormone therapy, male hormone disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 40 years old.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages